Share Name Share Symbol Market Type Share ISIN Share Description
Midatech Pharma LSE:MTPH London Ordinary Share GB00BRTL9B63 ORD 0.005P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +1.50p +4.55% 34.50p 33.00p 36.00p 34.50p 33.70p 34.50p 177,351 14:00:14
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.9 -29.3 -56.0 - 21.07

Midatech Pharma Share Discussion Threads

Showing 251 to 275 of 275 messages
Chat Pages: 11  10  9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
22/2/2018
06:58
Another new low. Those peak sales forecasts for both MTD201 and the brain cancer drug look pure fantasy to me. Sandostatin is not patent protected anymore and it looks like three generics will be on the market before MTD201 is launched in 2020. The price by that time will be way lower than now - something that the forecasts haven’t taken into account. Also the brain cancer drug has such a limited market that I have no idea how they have arrived at their figures. Bearing in mind that DARA seems to be incapable of marketing its existing drugs it’s very hard to fathom how they will be capable of selling 10-15 times the current sales level. Also what happens to the recently negotiated loan if MTD201 fails to achieve bioequivalence? We haven’t been told the terms and conditions attached to the loan but one would assume that it would be subject to meeting certain drug development goals and surely MTD201 bioequivalence is one of those goals. Would the loan then have to be repaid quickly leaving MTPH in desperate need of new cash just as the share price crashes further? Continous delays and a plethora of unanswered questions surround this company.
jamtomorrow2
14/2/2018
16:58
More delays on MTD-201. What is wrong with these people?
ih_433513
14/2/2018
09:57
That looks very impressive .
gary38
14/2/2018
09:56
Midatech Pharma PLC Trading UpdateSource: UK Regulatory (RNS & others)TIDMMTPHRNS Number : 8075EMidatech Pharma PLC14 February 201814 February 2018Midatech Pharma PLC("Midatech", "Company" or "Group")Trading updateMidatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, today provides a trading update ahead of its full year results for the twelve months ended 31 December 2017.With a diversified strategy, multiple sources of revenue and an innovative R&D pipeline, Midatech has made good progress across the Group. Based on unaudited results, and in line with market expectations, reported total net revenues for the twelve months ended 31 December 2017 are expected to be at least GBP7.4m (2016: GBP6.9m), including US product sales of GBP6.7m (2016: GBP5.2m), an increase of 29% on the previous year (32% increase in USD). Whilst still subject to final audit approval, the US operation also reached break-even in H2 2017. The board continues to focus on managing costs and the group net cash balance as at 31 December 2017 was GBP13.2m (2016: GBP17.6m), also in line with market expectations.
gary38
12/2/2018
22:54
Looked like he had been trying some of his products. Still factually encouraging I thought
qackers
12/2/2018
20:42
That TV guy who can telling whether someone is telling the truth or lying from facial and bodily movements/expressions would have a field day analysing Jim’s performance on the proactive video. That involuntary gulping - oh dear.
ih_433513
12/2/2018
04:18
Excellent - thanks for posting that.
edrifter
11/2/2018
14:14
Nice Update hxxp://www.proactiveinvestors.co.uk/companies/stocktube/8717/critical-year-ahead-of-drug-development-for-midatech-pharma-8717.html
riddlerone
16/1/2018
23:04
The share price is 45p for a reason. One failed trial, a loss making acquisition and two approvals to conduct a trial after 3 years as a public company. That’s all folks. But at least one shareholder seems happy.
jamtomorrow2
16/1/2018
15:12
and on what planet do you think they will get approvals without trials ?
luffness
16/1/2018
14:53
What we need are drug approvals not approvals to conduct trials. These last two ‘approvalsR17; are supposed to excite us? Personally I’m appalled it’s taken so long to get these two ‘approvalsR17;. 2019 read out of today’s trial - geez. What was the point of wasting money on buying loss making DARA when they aren’t going to have any of their own drugs to market through DARA for years. Management has lost focus completely. If MTD201 isn’t deemed to be bio-equivalent in 2018 I’m starting to think that the company may not survive. Personally I’d dump DARA and hopefully recover something for it. I suspect that DARA’s 2017 loss and continuing loss forecast for 2018 will be significant. So much for breakeven by late 2017.
jamtomorrow2
16/1/2018
07:30
Another announcement. Niche market but some potential
18bt
09/1/2018
23:02
MTD201 study approved!! Somewhat misleading headline! I was under the impression that it had been approved to commence ages ago. Nobody ever said the hold-up was due to not having EU approval. So the previously quoted reason for the hold-up of problems relating to gearing up to production levels at the Spanish lab was basically as misleading as the heading to today’s announcement. So when is this wretched trial actually going to start? It’s delay after delay after delay. No wonder the share price is so bombed out. Also why do we hear nothing about the success or otherwise of the compansionate UK program re childrens brain cancer? This had been going on for a couple of years now. If successful you’d have thought they’d be singing out the good news from the rooftops.
jamtomorrow2
09/1/2018
09:45
Very interesting RNS today Q-Octreotide (MTD201) is Midatech's treatment for carcinoid cancer and acromegaly built on its Q-SpheraTM sustained release platform technology. The somatostatin analogue treatment for carcinoid cancer and acromegaly is being developed as the first alternative version of the commercial leading product, Sandostatin® LAR (SLAR). During its pre-clinical programme, data suggested that Q-Octreotide has an equivalent profile to the Novartis SLAR and may offer some important advantages to clinicians and patients. Midatech believes that if these data are confirmed in the upcoming study Q-Octreotide could capture up to a 5% share of the market for SLAR, which is worth $2bn annually1. That's a potential £74m a year uplift if confirmed.
jimbo123elf
03/1/2018
12:02
There are 1.8m ADRs outstanding.
jamtomorrow2
03/1/2018
11:35
Looks like Yahoo didnt update shares in issue after the last placing
luffness
03/1/2018
11:29
Ok. So what would the shares outstanding figure on YahooUS refer to? Total shares converted to ADR's? It is also hard to see that the total ADR stock would have been rotated through 3 times. Possible I guess - but I have US ADR's, and with that level of demand I would have probably been getting phone calls, asking if I wanted to sell!
edrifter
03/1/2018
11:16
5.82m ADRs (yesterday’s Nasdaq volume) is about 3 times the total number of ADRs in existence. I checked.
jamtomorrow2
03/1/2018
02:43
Yahoo US quotes 48.72M outstanding shares - which I take to be the ADR's of which there is a float of 21.14M. UK 61.08M, with a float of 42.29M. US volume of 5,820,656 would represent 27% of the US float. 144k in the UK is paltry by comparison - which is in itself pretty interesting.
edrifter
02/1/2018
22:08
Only 75% up at close on volume of 5.79m ADRs. There can’t be many more than that number in existence can there? I see the high for the day was up 215%.
jamtomorrow2
02/1/2018
21:07
Some thing afoot
penciles2
02/1/2018
19:40
Following today's RNS which I view was positive, I can see this one running up much higher.
rathkum
02/1/2018
19:25
Up 150% tonight on Nasdaq on huge volume. Something going on?
jamtomorrow2
28/9/2017
08:45
you got a bit of news, don't think it is good though....
pugg1ey
26/7/2017
07:36
Positive update this AM. Monetisation some way off but looking good. Perhaps one more good bit of news in the next couple of months and we will see a re-rating.
gwatson56
Chat Pages: 11  10  9  8  7  6  5  4  3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20180223 06:35:00